Andrew Gray

Director, QA Clinical Therapeutic Area Head - Johnson & Johnson

Andrew is a member of Johnson and Johnson's R&D Quality organisation where hehas responsibility for risk-based audit strategies across each of the company’s clinical therapeutic areas. With an active interest in the use of RWE for regulatory decision making, Andrew was responsible for establishing the EUCOPE RWE Focus Group while working in Amgen’s Global R&D Policy organisation. He continues to actively participate in initiatives designed to develop quality standards for the use of RWE across the product development cycle. Prior to his return to the pharmaceutical industry, Andrew was a Deputy Director and Head of the Medicines Inspectorate at MHRA. Andrew has led international regulatory groups for the Organisation for Economic Cooperation and Development, the European Medicines Agency and the European Commission. Andrew’s experience includes 15 years in academic research and pharmaceutical early phase drug development, with a scientific background in cardiovascular disease and tissue repair.